Journal of Neurology · 2007 · 92 citations · 14 references
Life SciencesNeurologyNeuroscienceNeurodegenerationNeurogeneticsNeuropathologyBiomarkers Of NeurodegenerationCerebrospinal Fluid BiomarkersCreutzfeldt-jakob DiseaseNeurodegenerative DiseasesNeurodegenerative DisordersTau PathologyCerebrospinal Fluid 14-3-3 ProteinCerebrospinal Fluid MarkersCerebrospinal Fluid Neurodegeneration MarkersDiagnosis Of Creutzfeldt-jakob DiseaseNeuron-specific EnolaseSporadic Creutzfeldt-jakob Disease BiomarkersSporadic Creutzfeldt-jakob Disease DiagnosisTau Protein Biomarkers
BACKGROUND: The analysis of markers in the cerebrospinal fluid (CSF) is useful in the diagnosis of sporadic Creutzfeldt-Jakob disease (sCJD). However, the time at which the study of these markers is most sensitive remains controversal. OBJECTIVE: To assess the influence of time of sampling on the value of CSF tests in the diagnosis of sCJD. METHOD: In the framework of a multinational European study, we studied the results of 14-3-3, S100b, neurone specific enolase (NSE) and tau protein in 833 CSF samples from sCJD patients at different stages of disease and in 66 sequentially repeated lumbar punctures (LP). RESULTS: 14-3-3 and tau protein tended to increase in sensitivity from onset (88%, 81%) to the advanced stage (91%, 90%). This was significant only in the methionine-valine (MV) heterozygous group of patients at codon 129. The absolute levels of S100b (p < 0.05), NSE and tau protein increased in the last stage of disease. High levels of tau protein, NSE and S100b were associated with shorter survival times (p < 0.01). Sixty-six sCJD patients underwent repeated LP. These sCJD patients were younger, had longer disease durations and were more frequently MV at codon 129 (p < 0.001) than the whole group. 14-3-3 sensitivity increased from 64% to 82% in the second LP (p = 0.025) and 88% sCJD patients had at least one positive result. CONCLUSIONS: Sensitivity and absolute levels of CJD markers increased with disease progression and were modulated by the codon 129 genotype. Early negative results should be inter-preted with caution, especially in young patients or those who are MV at codon 129.
14
Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease
Markus Otto, Jens Wiltfang, Lukas Cepek et al. · Neurology · 2002 · 290 citations
CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease
Pascual Sánchez‐Juan, A. Green, Anna Ladogana et al. · Neurology · 2006 · 288 citations
Inga Zerr, Monika Bodemer, S. Räcker et al. · The Lancet · 1995 · 165 citations